Report Scope:
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.

Report Includes:

  • 24 data tables and 8 additional tables
  • An overview of the global market for human recombinant DNA
  • Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
  • Highlights of the market potential for human recombinant DNA, based on product, application, and region
  • Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
  • Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi